Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden
European Journal of Clinical Pharmacology · 2024-10 · 80 (10) · 1571-1580
DOI: 10.1007/s00228-024-03724-3 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 16.07.2024. Verfasst von Björn Wettermark und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden. bjorn.wettermark@farmaci.uu.se. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention, Cardiovascular Diseases, Primary Prevention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.
Abstract (Originalsprache)
Background
Age is a major risk factor for atherosclerotic cardiovascular disease (CVD) and death, but there has been a debate about benefit-risk of statin treatment in the elderly with limited evidence on benefits for primary prevention, while there is strong evidence for its use in secondary prevention.
Aim
The aim of this study was to provide an overview of statin utilization in primary and secondary prevention for patients 75–84 years and ≥ 85 years in the Swedish capital Region Stockholm in 2019.
Methods
This is a cross-sectional study based on the regional healthcare database VAL containing all diagnoses and dispensed prescription drugs for all 174,950 inhabitants ≥ 75 years old in the Stockholm Region. Prevalence and incidence were analyzed by sex, age, cardiovascular risk, substance, and the intensity of treatment.
Results
A total of 35% of all individuals above the age of 75 in the region were treated with statins in 2019. The overall incidence in this age group was 31 patients per 1000 inhabitants. Men, individuals 75–84 compared to ≥ 85 years of age, and those with higher cardiovascular risk were treated to a greater extent. Simvastatin was used primarily by prevalent users and atorvastatin by incident users. The majority was treated with moderate-intensity dosages and fewer women received high intensity treatment.
Conclusions
Statins are widely prescribed in the elderly. Physicians seem to consider individual cardiovascular risk when deciding to initiate statin treatment for elderly patients, but here may still be some undertreatment among high-risk patients (especially women and elderly 85 + years) and some overtreatment among patients with low-risk for CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden. bjorn.wettermark@farmaci.uu.se.
- Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.
- Academic Primary Health Care Centre, Stockholm Region, Stockholm, Sweden.
- Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institute and Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
Förderung
- Uppsala University
Zitieren
APA
Wettermark, B., Kalantaripour, C., Forslund, T., & Hjemdahl, P. (2024). Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden. European Journal of Clinical Pharmacology, 80(10), 1571-1580. https://doi.org/10.1007/s00228-024-03724-3
Vancouver
Wettermark B, Kalantaripour C, Forslund T, Hjemdahl P. Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden. European Journal of Clinical Pharmacology. 2024;80(10):1571-1580. doi:10.1007/s00228-024-03724-3
BibTeX
@article{Wettermark2024,
author = {Wettermark, Björn and Kalantaripour, Camelia and Forslund, Tomas and Hjemdahl, Paul},
title = {Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
volume = {80},
number = {10},
pages = {1571--1580},
doi = {10.1007/s00228-024-03724-3}
}
EUVIMED